New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain New retrospective...

Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment Marking a major step forward in the evolution of...

Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. The completion of this...

Boston Scientific Corporation (NYSE:BSX) today announced the first German patient enrolment in the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization, a prospective multicentre...

Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control Boston Scientific Corporation (NYSE: BSX) has received CE...

An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity...

REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from the first 60 patients enrolled in the...

In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II...

A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years, according to data published online in a key medical...

First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...